Covid-era coercion and misinformation bred public distrust, but the vaccines did save countless lives.

With that in mind, let's consider two stocks that people in their 30s -- who are still a good distance away from retirement - ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million ...

Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Moderna may offer substantial upside, but it's essential to consider the associated risks. Since hitting their peak in late ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna’s EP’949 patent. This decision affirms the ...

The average short interest in the S&P 500 Health Care Index Sector (XLV) dipped slightly in July to 1.95% from 1.96% in June.

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

Illinois researchers, including some working on vaccines for cancer and rare diseases, worry the federal government turning ...